Zhike Powder Veterinary Grade API is supplied as a crystalline free-flowing powder intended for the formulation of tablets, injections, capsules, powders, granules, premixes, and solutions. The product model ZK-VAPI-102 is assigned to the multi-dosage-form grade, with suffix designations ZK-VAPI-102-T for direct tableting, ZK-VAPI-102-I for injectable and solution processing, and ZK-VAPI-102-PM for premix and oral powder applications. Release specifications are layered by route rather than by a single universal monograph. Assay is determined by HPLC against a certified veterinary reference standard with an acceptance interval of 98.0–102.0% on the dried basis. Water content by Karl Fischer is controlled to ≤0.5% for solid oral and premix lots, while injectable-destined lots are dried to ≤0.3% when non-aqueous solvents require low moisture. Endotoxin release for parenteral-use lots is set from the maximum total daily dose in the target species and is typically ≤0.25 EU/mg; oral and premix lots may be released at a less stringent internal limit but are still verified during process validation. Residual solvents are controlled according to USP <467> Option 1, elemental impurities are controlled by USP <232> and USP <233>, and subvisible particulates after reconstitution are assessed using USP <788> for injectable presentations. The powder is packaged in double low-density polyethylene liners inside fibre drums for solid dosage forms and in aluminium foil laminate pouches under nitrogen for injectable-grade lots. Actual release values must be obtained from the lot-specific certificate of analysis because batch-to-batch variability in particle size, moisture, and impurity profile is normal for multi-tonne veterinary API campaigns.

What Limits Direct Compression Performance for Veterinary APIs?

Direct compression of the API is constrained less by chemical assay than by bulk powder rheology and particle-size distribution. The tableting-grade lot is milled to a laser-diffraction D₅₀ of 150–250 µm and D₉₀ of ≤350 µm when tested by USP <429>. Compressibility index and Hausner ratio are measured by USP <1174>; a lot intended for direct compression should maintain a Carr index ≤18 and a Hausner ratio ≤1.25. If the Hausner ratio rises above 1.35, the material is diverted to wet granulation or roller compaction because flow into 12 mm standard concave tooling becomes erratic. A rotary tablet press operated at a main compression force of 15–20 kN and precompression force of 5 kN is used for compactibility trials. Ejection force is monitored with an instrumented upper punch; values above 800 N indicate lubrication failure or overlubrication with magnesium stearate. Because the API is crystalline and has low moisture sensitivity, a Karl Fischer window of 0.3–0.5% is maintained to prevent brittle fracture at lower moisture and punch filming at higher moisture. Direct compression blends containing 25.0 wt% API, 70.0 wt% microcrystalline cellulose, and 5.0 wt% crospovidone are used as a formulation screening matrix, but the exact excipient ratios are adjusted for target species palatability and acid resistance. Published data for this specific API configuration are limited; therefore the above ranges represent process-control targets, not guaranteed release values.

For capsule and granule operations, the milled powder is typically densified using a roller compactor with 1.5 mm and 3.0 mm screen sizes to improve flow and reduce dust generation. The granulated intermediate is filled into hard capsules at target fill weights from 50 mg to 400 mg per unit using dosator or tamping-pin machines. Tamping-pin stations are set to 15–20 mm pin height and 60–80% powder level; fill weight variability should remain below ±3.0% relative standard deviation across 10 min run samples. Dry granulation is preferred when the API shows sensitivity to moisture or heat. If wet granulation is required for high-dose tablets, the binder solution is added by high-shear mixer at an impeller speed of 200–300 rpm and a chopper speed of 1000–1500 rpm, with total granulation time not exceeding 8–10 min to avoid overgranulation. Granule moisture is dried in a fluid-bed dryer with inlet air at 50–60°C until loss on drying is ≤2.0%. Capsule formulations using the API at 40.0 wt% loading require a flow aid such as colloidal silicon dioxide at 0.5–1.0 wt% and a lubricant level below 0.5 wt% to prevent dissolution slowdown. The powder grade is also suitable for oral powders and granules for administration in feed or drinking water; for this route, particle-size distribution is coarser with D₅₀ of 250–425 µm to reduce dust and improve mixing with feed matrices.

Sterile Filtration and Endotoxin Thresholds in Injectable Presentations

Injectable presentations impose a different control envelope because the same crystalline powder must dissolve completely and remain free of pyrogenic contamination. For non-aqueous injections, water content is reduced to ≤0.3% to avoid hydrolysis and to support sterilisation by dry heat. Aqueous solutions are prepared at concentrations from 10 mg/mL to 150 mg/mL depending on the target species dose. Clarity after dissolution is checked by visual inspection against light-background and dark-background panels; subvisible particulate matter is limited by USP <788> Method I for containers up to 100 mL. Before sterile filtration, the bulk solution is passed through a 0.45 µm polyethersulfone prefilter and then through a 0.22 µm sterilising-grade membrane. The filtration train is validated for bacterial retention according to ASTM F838-20 and for extractables by USP <1663> / USP <1664>. If the API particle size is not reduced below 100 µm D₉₀ before dissolution, the sterilising filter can clog and throughput falls below the minimum batch size; therefore injectable lots are milled to D₉₀ ≤75 µm. Endotoxin limit is calculated as K/M, where K is 5 EU/kg for small-volume parenterals and M is the maximum bolus dose in kg per kg of body weight. For a representative 0.5 mg/kg dose, the resulting limit is 10 EU/mg; the manufacturer’s release target of ≤0.25 EU/mg provides a safety factor. Solution stability studies are conducted in glass vials and polypropylene syringes at 2–8°C, 25°C/60% RH, and 40°C/75% RH with photostability according to ICH Q1B. Published data for this specific product’s long-term stability are not public because the dossier remains under regulatory review for several target species.

In dry premix and oral powder manufacturing, the primary failure mode shifts from flowability to segregation and inhomogeneity after mixing. The premix-grade lot is prepared with a D₅₀ of 250–425 µm and a bulk density of 0.45–0.60 g/cm³, which is matched to common feed carriers such as ground corn, soybean meal, or whey powder. A horizontal ribbon blender with fill volume 60–70% of rated capacity and agitator speed 40–50 rpm is a standard production-scale unit. Mixing time is validated by sampling 10 locations after 10 min, 15 min, and 20 min; the coefficient of variation of assay should not exceed 5.0%. Blend uniformity is tested by USP <905> for stored powders if the product is claimed as a finished dosage form. Overmixing beyond 20 min at the validated speed can increase static charge and produce particle attrition, which raises the fine fraction below 75 µm and increases segregation during discharge. Sifting segregation is controlled by keeping the ratio of API D₅₀ to carrier D₅₀ between 0.8 and 1.2. The powder is also used in granules for oral solutions; in that application, the granule is wet-massed with a maltodextrin or sucrose carrier and dried to a moisture specification of ≤2.0%, then sieved through 850 µm aperture. The final oral solution is prepared by reconstitution in potable water at 20–25°C under continuous agitation for 5 min; if the solution is not consumed within 24 h, the manufacturer’s stability data for in-use conditions must be followed.

When Premix Homogeneity Fails Under High-Moisture Feed Conditions

When relative humidity in the mixing suite exceeds 60%, the powder may sorb moisture, increasing the risk of particle agglomeration and loss of blend uniformity. The API is hygroscopic to a limited degree, but the premix carrier often has a higher moisture uptake. A loss on drying shift from 0.5% to 1.5% can raise the angle of repose from ≤35° to ≥45°, which is outside the acceptable range for gravity-fed packaging lines. Published data for this specific product configuration are limited; however, general powder handling measurements indicate that carrier moisture above 12.0% at the time of addition can increase blend assay coefficient of variation. To prevent this, the premix-grade API is double-bagged with desiccant and the mixing suite is maintained at ≤50% RH. If the product is milled into a wet granulation premix, the water activity of the final blend should be kept below 0.60 to limit microbial growth and caking. Packaging is selected to provide a moisture vapour transmission rate below 0.1 g/m²/day for aluminium foil liners; fibre drums without foil are unsuitable for long-term storage in tropical environments. These constraints are not identical to those for the injectable grade, which is protected under nitrogen and released with lower water content.

The veterinary API grade differs from technical-grade and feed-additive powders in the control of impurities, particle size, and documentation. The table below compares the three grades. The veterinary grade is the only one released against a compendial impurity profile with specified individual impurities below 0.5% and total impurities below 1.0%. Technical grades may be sold on assay alone and may carry synthesis-related impurities above 1.0%. Premix and feed-grade powders are often controlled only for potency, loss on drying, and heavy metals; they are not released for injectable use because endotoxin and subvisible particulates are not batch-tested. The multi-dosage-form grade adds residual solvent testing per USP <467>, elemental impurities per USP <232>, and particle-size distribution per USP <429>. Additionally, the veterinary API grade is supported by a valid veterinary master file or registration dossier, stability data under ICH Q1A(R2) conditions, and a certificate of analysis for every batch. In contrast, a technical-grade material may be repacked without a complete regulatory chain of custody. These differences are operational, not merely marketing distinctions.

Does Multi-Dosage-Form Suitability Require Separate Specification Layers?

Separate specification layers are mandated because a single set of release limits cannot simultaneously satisfy the low-moisture and low-endotoxin requirements of injections and the larger particle-size needs of premixes. The injectable layer controls water content ≤0.3%, endotoxin ≤0.25 EU/mg, and D₉₀ ≤75 µm. The solid oral layer allows water content ≤0.5%, does not require batch endotoxin release, and permits a larger D₅₀ of 150–250 µm. The premix layer uses a coarser particle size with D₅₀ 250–425 µm and adds bulk density control because feed mill mixing is less tolerant of fine dust. If the same batch is to be used across all three layers, it must meet the most stringent criterion for every parameter; this generally requires injectable-grade drying and milling, followed by classification into the required fractions. The trade-off is that milling to the injectable specification may produce a fine fraction that is problematic for direct compression unless the tableting grade is separately processed. The specification architecture therefore includes grade-specific suffixes in the product model code and separate certificates of analysis for each suffix. Stability data are generated for each physical presentation; bracketing and matrixing are applied according to ICH Q1D when the packaging and strength are close enough to justify reduced testing.

Compliance Documentation and Stability-Indicating Assay Requirements

Stability-indicating HPLC with photodiode array detection is used to assign the re-test period under long-term 25°C/60% RH and accelerated 40°C/75% RH conditions. The current packaging for injectable lots is an aluminium foil laminate pouch under nitrogen with a desiccant sachet; the package prevents moisture ingress below 0.1 g/m²/day and is sealed after vacuum purging. Solid oral and premix lots are packaged in double low-density polyethylene liners inside fibre drums with sealed desiccant. The re-test period for each grade is assigned only after at least 12 months of long-term data and six months of accelerated data; no re-test period is extrapolated beyond the bracketing matrix without statistical support. The product is released against a certificate of analysis that includes assay, related substances, water content, residual solvents, particle size, bulk density, and, for injectable lots, endotoxin and subvisible particulates after reconstitution. The manufacturing process is controlled under current good manufacturing practice for veterinary medicinal products, and the facility is expected to maintain validated cleaning procedures to prevent cross-contamination with beta-lactam and sulfonamide products. Transportation is conducted under temperature-controlled conditions when the injectable grade is shipped; oral and premix lots may be shipped at ambient temperature if the stability data support it. Documentation includes a batch manufacturing record, packaging record, and a signed certificate of analysis; the technical dossier should be consulted before formulation because the API shows route-specific constraints that are not captured by a single specification.